Olema Pharmaceuticals (OLMA) Non-Current Assets (2020 - 2026)
Olema Pharmaceuticals (OLMA) posted quarterly Non-Current Assets of $17.4 million for Q1 2026, up 34.22% year-over-year from $13.0 million in Q1 2025, and down 3.13% quarter-over-quarter from $18.0 million in Q4 2025.
Olema Pharmaceuticals (OLMA) Non-Current Assets (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has reported Non-Current Assets for 7 consecutive years, with $17.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 34.22% year-over-year to $17.4 million; the TTM figure through Mar 2026 stood at $67.8 million (up 35.51% YoY), while the FY2025 annual figure was $18.0 million, up 43.75% from the prior year.
- Non-Current Assets retreated to $17.4 million in Q1 2026 per OLMA's latest filing, from $18.0 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $18.1 million in Q3 2025 and bottomed at $6.1 million in Q2 2023.
- Historically, Non-Current Assets has averaged $11.3 million across 5 years, with a median of $11.6 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Assets soared 595.37% — and 2023, when it dropped 19.26%.
- Olema Pharmaceuticals' Non-Current Assets stood at $6.7 million in 2022, then jumped by 54.64% to $10.4 million in 2023, then gained by 19.88% to $12.5 million in 2024, then soared by 43.75% to $18.0 million in 2025, then decreased by 3.13% to $17.4 million in 2026.
- Business Quant data shows OLMA's Non-Current Assets at $17.4 million in Q1 2026, $18.0 million in Q4 2025, and $18.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Olema Pharmaceuticals | 930.10 Mn | 930.10 Mn | - | 16.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.70 Mn |
| Mar 31, 2026 | 17.42 Mn |
| Dec 31, 2025 | 17.98 Mn |
| Sep 30, 2025 | 18.12 Mn |
| Jun 30, 2025 | 14.28 Mn |
| Mar 31, 2025 | 12.98 Mn |
| Dec 31, 2024 | 12.51 Mn |
| Sep 30, 2024 | 12.18 Mn |
| Jun 30, 2024 | 12.37 Mn |
| Mar 31, 2024 | 11.60 Mn |
| Dec 31, 2023 | 10.43 Mn |
| Sep 30, 2023 | 10.79 Mn |
| Jun 30, 2023 | 6.12 Mn |
| Mar 31, 2023 | 6.37 Mn |
| Dec 31, 2022 | 6.75 Mn |
| Sep 30, 2022 | 6.94 Mn |
| Jun 30, 2022 | 7.57 Mn |
| Mar 31, 2022 | 7.20 Mn |
| Dec 31, 2021 | 5.26 Mn |
| Sep 30, 2021 | 1.52 Mn |